Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 5/20 | 0.38 |
| ▸ | CASP7 | P55210 | 5/20 | 0.38 |
| ▸ | USP2 | O75604 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399671 | 0.89 | CYP1A2 (0.41) | CYP1A2CYP3A4TSHRMAPK1CYP2C19 | |
| SCHEMBL4394610 | 0.89 | ALDH1A1 (0.39) | CYP1A2CYP3A4TSHRMAPK1CYP2C19 | |
| SCHEMBL4397399 | 0.88 | ADORA3 (0.41) | CYP1A2CYP3A4TSHRCYP2C19ALDH1A1 | |
| SCHEMBL4397696 | 0.86 | ALDH1A1 (0.51) | TSHRCYP2C19ALDH1A1HSD17B10HPGD | |
| SCHEMBL4397474 | 0.85 | CYP1A2 (0.41) | CYP1A2CYP3A4TSHRMAPK1CYP2C19 | |
| SCHEMBL4399163 | 0.85 | SMN1; SMN2 (0.47) | CYP1A2CYP3A4MAPK1CYP2C19ALDH1A1 | |
| SCHEMBL4394462 | 0.80 | CYP1A2 (0.39) | CYP1A2CYP3A4TSHRMAPK1CYP2C19 | |
| SCHEMBL4394500 | 0.80 | TP53 (0.43) | TSHRALDH1A1HPGDLMNAGRM5 | |
| SCHEMBL4399245 | 0.79 | KDM4E (0.39) | TSHRALDH1A1HPGDLMNAKDM4E | |
| SCHEMBL4393854 | 0.79 | ADORA3 (0.39) | ALDH1A1HPGDLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919921-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-1919921-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7494984-B2 | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-24 | — | — | US | disclosed |
| US-7494984-B2 | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-24 | — | — | US | disclosed |
| US-7494984-B2 | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-24 | — | — | US | disclosed |
| WO-2007027754-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | CCNI, APOBEC3C, CDKN1A | CYP1A2 215/4885CYP3A4 170/4885TSHR 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.